Abstract:

Objective　To observe the application of ceftazidime injection in adjuvant chemotherapy for lung cancer and its prevention and control effect of lung infection. Methods　It was a randomized controlled trial. A total of 98 patients with lung cancer admitted to The First People's Hospital of Shangqiu City from January 2020 to August 2021 were included as the research objects. They were divided into an observation group and a control group by the lottery method, with 49 cases in each group. In the observation group, there were 30 males and 19 females, aged (55.33±5.16) years; in the control group, there were 33 males and 16 females, aged (55.25±5.32) years. Both groups received chemotherapy, and the observation group received ceftazidime injection as adjuvant chemotherapy. The changes of serum inflammatory factors and blood gas indexes before and after treatment, the changes of Clinical Pulmonary Infection Score (CPIS) after 1, 3, and 7 days of treatment, and the incidence of pulmonary infection were compared between the two groups. A 1-year follow-up was conducted after treatment to compare the long-term survival of the two groups. χ² test and independent sample t test were used. Results　Before treatment, there were no statistically significant differences in the serum inflammatory factors and blood gas indexes between the two groups (all P>0.05). After treatment, the levels of C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and other inflammatory factors were increased in both groups, but the above indexes in the observation group were lower than those in the control group (all P<0.05); the partial pressure of arterial oxygen (PaO₂), oxygen saturation (SaO₂), oxygenation index (PaO₂/FiO₂), and other blood gas indexes were decreased in both groups, but the above indexes in the observation group were higher than those in the control group (all P<0.05). The CPIS of the observation group after 1, 3, and 7 days of treatment were lower than those of the control group [(6.97±1.21) points vs. (7.62±1.35) points, (5.82±0.74) points vs. (6.33±0.65) points, (4.52±0.45) points vs. (5.03±0.17) points], and the incidences of pulmonary infection were lower than those of the control group [10.20% (5/49) vs. 20.41% (10/49), 4.08% (2/49) vs. 14.29% (7/49), 0.20% (1/49) vs. 10.20% (5/49)], with statistically significant differences (all P<0.05). During the follow-up period, the scores of all dimension of Functional Assessment of Cancer Therapy - Lung cancer (FACT-L) in the observation group were higher than those in the control group (all P<0.05). Conclusion　The use of ceftazidime injection as an adjuvant therapy during chemotherapy for lung cancer patients can promote the recovery of inflammatory response and arterial blood gas indicators, which has positive significance in reducing the risk of lung infection and improving the long-term quality of life.

Key words:

Lung cancer, Chemotherapy, Ceftazidime, Pulmonary infection, Prevention and control effect

摘要：

目的　观察头孢他啶注射液辅助肺癌化疗对患者肺部感染的防治效果。方法　本研究为随机对照试验，病例纳入商丘市第一人民医院2020年1月至2021年8月期间收治的98例肺癌患者为研究对象，采用抽签法，将其均分为观察组和对照组，每组49例。观察组中男30例、女19例，年龄（55.33±5.16）岁；对照组中男33例、女16例，年龄（55.25±5.32）岁。两组患者均统一接受化疗，观察组采用头孢他啶注射液辅助化疗。比较两组治疗前后的血清炎症因子、血气指标变化情况，治疗1、3、7 d的临床肺部感染评分（CPIS）变化情况及肺部感染发生率，并于治疗后开展为期1年的随访，比较两组患者远期生存情况。采用χ²检验、独立样本t检验。结果　治疗前，两组患者的血清炎症因子及血气指标差异均无统计学意义（均P>0.05）；治疗后，两组C-反应蛋白（CRP）、降钙素原（PCT）、白细胞介素-6（IL-6）等炎症因子水平均升高，但观察组上述指标低于对照组（均P<0.05）；两组动脉氧分压（PaO₂）、动脉血氧饱和度（SaO₂）、氧合指数（PaO₂/FiO₂）等血气指标水平均下降，但观察组上述指标高于对照组（均P<0.05）。观察组治疗1、3、7 d后的CPIS低于对照组［（6.97±1.21）分比（7.62±1.35）分、（5.82±0.74）分比（6.33±0.65）分、（4.52±0.45）分比（5.03±0.17）分］，肺部感染发生率低于对照组［10.20%（5/49）比20.41%（10/49）、4.08%（2/49）比14.29%（7/49）、0.20%（1/49）比10.20%（5/49）］，差异均有统计学意义（均P<0.05）。随访期间，观察组的肺癌患者生存质量测定量表（FACT-L）各维度评分均高于对照组（均P<0.05）。结论　在肺癌患者化疗期间采用头孢他啶注射液辅助治疗可促进患者炎症反应以及动脉血气指标恢复，对降低肺部感染发生风险及改善远期生存质量均有积极意义。

关键词:

肺癌, 化疗, 头孢他啶, 肺部感染, 防治效果